Testimonies & Filings
Navigate forward to interact with the calendar and select a date. Press the question mark key to get the keyboard shortcuts for changing dates.
Navigate backward to interact with the calendar and select a date. Press the question mark key to get the keyboard shortcuts for changing dates.
Advising Policymakers
ITIF provides policy expertise to governments around the world, frequently testifying and filing public comments for official hearings, inquiries, and regulatory proceedings.
- Subscribe to our email newsletters and follow us on Twitter to stay abreast.
April 11, 2025
Comments to the FCC Regarding Identifying and Eliminating Unnecessary Rules and Regulations
Consumers will benefit from updated Federal Communications Commission rules that recognize technical and economic realities and foster a dynamic marketplace for years to come.
April 11, 2025
Comments to the FCC Regarding Submarine Cable Landing Licenses
Reforming the submarine cable landing license review process is essential for maintaining US leadership in global telecommunications infrastructure while ensuring appropriate national security protections.
April 11, 2025
Comments Before the Malaysia Competition Commission Regarding Assessment of Malaysia’s Digital Markets
While the Interim Report of the Market Review on the Digital Economy Ecosystem under the Competition Act 2010 reflects a valuable step toward understanding market trends, it does not present clear evidence of systemic market failure that would warrant prescriptive regulatory intervention.
April 9, 2025
Comments Before the House Committee on Energy and Commerce Regarding Data Privacy
A reasonable compromise on federal data privacy should protect and promote innovation by minimizing compliance costs and restrictions on data use, as well as address concrete privacy harms, improve transparency requirements, and strengthen oversight and enforcement.
April 3, 2025
Testimony Before the House Judiciary Committee Regarding Artificial Intelligence Trends in Innovation and Competition
AI provides no reason at this time for either heavy-handed enforcement of our antitrust laws or fundamental changes to them. The right approach is to maintain antitrust law’s traditional focus on promoting competition and innovation by proscribing collusive and exclusionary anticompetitive conduct.
March 20, 2025
Memo to the U.S. Treasury Department Regarding President Trump’s America First Trade Policy
The administration should address concerns related to counterfeit products, discriminatory digital taxes, and investment controls for critical technologies with measures to protect American innovation while promoting fair, rules-based trade principles that benefit the U.S. economy and support U.S. technological leadership.
March 20, 2025
Memo to the U.S. Commerce Department Regarding President Trump’s America First Trade Policy
The administration should address mercantilist policies that systematically disadvantage American businesses and workers with corrective measures such as strategic enforcement actions, reciprocal tariffs, expanded trade agreements, and stronger digital trade protections.
March 20, 2025
Memo to the U.S. Trade Representative Regarding President Trump’s America First Trade Policy
The administration should address trade imbalances, discriminatory regulations, and digital trade restrictions imposed by China, India, and the European Union, among others. Targeted policy responses may include reciprocal tariffs, digital trade enforcement, fair pricing mechanisms, and strengthened trade agreements to ensure a level playing field for U.S. businesses.
March 14, 2025
Comments to the Office of Science and Technology Policy on the Development of an AI Action Plan
The Center for Data Innovation outlined seven policy priorities we believe to be most critical for the AI Action Plan, along with specific actions the administration should take.
February 27, 2025
Comments to CMS on the List of Drugs for Price Setting Starting in 2027
Recent policies permitting CMS price setting are hamstringing the U.S. biopharmaceutical industry, as they reduce incentives for pharmaceutical companies to invest in future drug R&D to create life-improving and life-saving medicines.